Aktienanalyse zu Addex Therapeutics Ltd (ADXN)ADXNAddex Therapeutics Ltd

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. It operates in the Healthcare sector.

Addex Therapeutics Ltd (ADXN) is currently not a strong buy due to its ongoing financial challenges and negative performance trends. The stock has experienced a year-to-date decline of 64.28% and a 52-week low of 2.56, indicating significant volatility. Although the RSI is at 41.217, suggesting it is nearing oversold conditions, the forward P/E ratio is 0, indicating no earnings expected in the near term. The company has reported a net loss of CHF 3.46 million for H1 2026, which is wider than the previous year, and its gross margin has fluctuated, showing instability. The main risk is the high net loss per share of CHF 0.03, which raises concerns about profitability moving forward.